Rapp Marion, Baernreuther Jessica, Turowski Bernd, Steiger Hans-Jakob, Sabel Michael, Kamp Marcel A
Department of Neurosurgery, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Department of Neurosurgery, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
World Neurosurg. 2017 Jul;103:733-740. doi: 10.1016/j.wneu.2017.04.053. Epub 2017 Apr 19.
BACKGROUND: Typical recurrence of glioblastoma occurs locally, usually within 2 cm from the original lesion. With improvement of surgical techniques, more aggressive surgical strategies have become feasible, resulting in a significantly increased rate of complete resection. We investigated whether these improvements are also reflected by tumor recurrence pattern. METHODS: Inclusion criteria were first diagnosis of glioblastoma with standard adjuvant radiochemotherapy and histologically proven tumor recurrence. Patients were divided according to recurrence pattern: local recurrence, distant recurrence, or both recurrence patterns. Data were correlated with extent of resection, molecular tumor configuration, clinical status, and survival data. RESULTS: This single-center retrospective study included 97 patients with glioblastoma treated between 2007 and 2014. Local, distant, and combined tumor recurrence patterns were observed in 77 (79.3%), 10 (10.3%), and 10 patients (10.3%). Median progression-free survival of all patients was 8 months; median overall survival was 20 months. Median progression-free survival was 7 months for patients with local recurrence, 13 months for patients with distant recurrence, and 9 months for patients with both recurrence patterns (P = 0.646). Median overall survival in the 3 groups was 21 months, 20 months, and 14 months (P = 0.098). No correlation between methylguanine-deoxyribonucleic acid methyltransferase methylation status and recurrence pattern was observed. CONCLUSIONS: Despite complete resection of contrast-enhancing tumor, most recurrences occurred locally. Patients with distant tumor recurrence demonstrated increased progression-free survival. Therefore, to gain local control, we may need to shift toward a more aggressive supramarginal resection, using extensive intraoperative monitoring to avoid permanent deficits.
背景:胶质母细胞瘤的典型复发发生在局部,通常在距原发灶2厘米范围内。随着手术技术的改进,更积极的手术策略已变得可行,导致完全切除率显著提高。我们研究了这些改进是否也反映在肿瘤复发模式上。 方法:纳入标准为首次诊断为胶质母细胞瘤并接受标准辅助放化疗且经组织学证实肿瘤复发。患者根据复发模式分为:局部复发、远处复发或两种复发模式均有。数据与切除范围、分子肿瘤构型、临床状态和生存数据相关。 结果:这项单中心回顾性研究纳入了2007年至2014年期间接受治疗的97例胶质母细胞瘤患者。观察到局部、远处和合并肿瘤复发模式的患者分别为77例(79.3%)、10例(10.3%)和10例(10.3%)。所有患者的无进展生存期中位数为8个月;总生存期中位数为20个月。局部复发患者的无进展生存期中位数为7个月,远处复发患者为13个月,两种复发模式均有的患者为9个月(P = 0.646)。三组患者的总生存期中位数分别为21个月、20个月和14个月(P = 0.098)。未观察到甲基鸟嘌呤 - 脱氧核糖核酸甲基转移酶甲基化状态与复发模式之间的相关性。 结论:尽管增强肿瘤已完全切除,但大多数复发仍发生在局部。远处肿瘤复发的患者无进展生存期延长。因此,为了实现局部控制,我们可能需要转向更积极的超边缘切除,采用广泛的术中监测以避免永久性神经功能缺损。
World Neurosurg. 2017-7
Int J Radiat Oncol Biol Phys. 2014-9-11
Int J Radiat Oncol Biol Phys. 2010-10-6
Clin Neurol Neurosurg. 2015-8
Acta Neurochir (Wien). 2025-8-8
BMC Med Imaging. 2025-7-30
Chin Neurosurg J. 2025-6-2
Int J Clin Oncol. 2025-5-22
Nat Rev Clin Oncol. 2025-5-14
Pharmaceuticals (Basel). 2025-3-6